Sobi appoints new VP and Commercial Therapeutic Area Head Haemophilia

Philip Wood joined Sobi in March 2012 as the Global Strategic Lead for the company`s Haemophilia A team, focusing on the pre-launch platform for the potential Factor VIII product. Prior to joining Sobi, Wood worked for both Wyeth and Pfizer in various positions of increasing responsibility from sales representative to European Director and European Specialty Asset Team Leader where he was responsible for the UK and then European re-launch of ReFacto® and Benefix®.  

 

"Philip brings significant launch and commercialization experience from the Haemophilia field to this role, and we are pleased that he will bring an integrated cross-functional approach to what we expect to be our most important program in the coming years", said Alan Raffensperger, COO.

 

Together with its partner Biogen Idec, Sobi currently has two on-going paediatric phase III trials, KIDS A-LONG and KIDS B-LONG in addition to the on-going open label extension studies from the adult phase 3 trials. Sobi expects to release top line data from these trials during 2014.